SU1083909A3 - Способ получени 6-замещенных производных пиранона - Google Patents
Способ получени 6-замещенных производных пиранона Download PDFInfo
- Publication number
- SU1083909A3 SU1083909A3 SU813254246A SU3254246A SU1083909A3 SU 1083909 A3 SU1083909 A3 SU 1083909A3 SU 813254246 A SU813254246 A SU 813254246A SU 3254246 A SU3254246 A SU 3254246A SU 1083909 A3 SU1083909 A3 SU 1083909A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- phenyl
- halogen
- compounds
- alkyl
- hydrogen
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical class O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 title description 3
- -1 cyano, 5-tetrazolyl Chemical group 0.000 claims abstract description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 8
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 4
- 239000001257 hydrogen Substances 0.000 claims abstract 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 21
- 208000006673 asthma Diseases 0.000 abstract description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 abstract description 4
- 150000003839 salts Chemical class 0.000 abstract description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 abstract 1
- 206010045240 Type I hypersensitivity Diseases 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 239000000203 mixture Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 241000700198 Cavia Species 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- VOLMSPGWNYJHQQ-UHFFFAOYSA-N Pyranone Natural products CC1=C(O)C(=O)C(O)CO1 VOLMSPGWNYJHQQ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RNQWXOKSUCPOFS-UHFFFAOYSA-N 1,4-dioxan-2-ol Chemical compound OC1COCCO1 RNQWXOKSUCPOFS-UHFFFAOYSA-N 0.000 description 1
- LSTAHPMLLDYWKN-ZHACJKMWSA-N 2-[(e)-2-phenylethenyl]chromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C=C1\C=C\C1=CC=CC=C1 LSTAHPMLLDYWKN-ZHACJKMWSA-N 0.000 description 1
- PEYODCCEJQCEBL-UHFFFAOYSA-N 2-methyl-6-phenylpyran-4-one Chemical compound O1C(C)=CC(=O)C=C1C1=CC=CC=C1 PEYODCCEJQCEBL-UHFFFAOYSA-N 0.000 description 1
- PXPNSQMWVPLERM-UHFFFAOYSA-N 2-methylchromen-4-one Chemical compound C1=CC=C2OC(C)=CC(=O)C2=C1 PXPNSQMWVPLERM-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- PVKMZCLHQYRBEK-UHFFFAOYSA-N 4-oxo-6-(2-phenylethenyl)pyran-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC(=O)C=C1C=CC1=CC=CC=C1 PVKMZCLHQYRBEK-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7912062 | 1979-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1083909A3 true SU1083909A3 (ru) | 1984-03-30 |
Family
ID=10504371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU813254246A SU1083909A3 (ru) | 1979-04-05 | 1981-03-10 | Способ получени 6-замещенных производных пиранона |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US4304728A (enExample) |
| JP (1) | JPS55133375A (enExample) |
| AR (4) | AR224149A1 (enExample) |
| AT (1) | AT371456B (enExample) |
| AU (1) | AU536369B2 (enExample) |
| BE (1) | BE882643A (enExample) |
| CA (1) | CA1142526A (enExample) |
| CH (1) | CH645370A5 (enExample) |
| CS (4) | CS222199B2 (enExample) |
| DD (1) | DD150001A5 (enExample) |
| DE (1) | DE3012584A1 (enExample) |
| DK (1) | DK142080A (enExample) |
| ES (1) | ES8104267A1 (enExample) |
| FI (1) | FI801019A7 (enExample) |
| FR (2) | FR2453169A1 (enExample) |
| GB (2) | GB2123813B (enExample) |
| GR (1) | GR67747B (enExample) |
| HU (1) | HU182115B (enExample) |
| IE (1) | IE49658B1 (enExample) |
| IL (1) | IL59747A (enExample) |
| IT (1) | IT1143085B (enExample) |
| LU (1) | LU82335A1 (enExample) |
| NL (1) | NL8002024A (enExample) |
| NZ (1) | NZ193344A (enExample) |
| PH (1) | PH16517A (enExample) |
| PL (4) | PL123812B1 (enExample) |
| PT (1) | PT71049A (enExample) |
| RO (3) | RO84586B (enExample) |
| SE (1) | SE8002514L (enExample) |
| SU (1) | SU1083909A3 (enExample) |
| YU (1) | YU91980A (enExample) |
| ZA (1) | ZA801978B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4644071A (en) * | 1984-07-11 | 1987-02-17 | G. D. Searle & Co. | Aralkoxy and aryloxyalkoxy kojic acid derivatives |
| DK59688A (da) * | 1987-03-20 | 1988-09-21 | Hoffmann La Roche | Styrylketoner |
| ES2166991T3 (es) * | 1996-04-26 | 2002-05-01 | Daiichi Seiyaku Co | Procedimiento para la preparacion de tetrahidroindolizinas. |
| TW587079B (en) * | 1998-09-25 | 2004-05-11 | Almirall Prodesfarma Ag | 2-phenylpyran-4-one derivatives |
| PE20011333A1 (es) * | 2000-03-16 | 2002-01-16 | Almirall Prodesfarma Ag | Derivados de 2-fenilpiran-4-ona como inhibidores de ciclooxigenasa 2 |
| CN1239472C (zh) * | 2000-06-16 | 2006-02-01 | 布里斯托尔-迈尔斯斯奎布公司 | Hiv整合酶抑制剂 |
| ES2213485B1 (es) * | 2003-02-13 | 2005-12-16 | Almirall Prodesfarma, S.A. | Derivados de la 2-fenilpiran-4-ona. |
| US8598086B2 (en) | 2009-06-08 | 2013-12-03 | Dow Agrosciences, Llc. | 3-halo-(arly)-4-iminotetrahydropicolinates and their use as herbicides |
| US8252938B2 (en) | 2009-06-08 | 2012-08-28 | Dow Agrosciences, Llc. | Process for the preparation of 6-(aryl)-4-aminopicolinates |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4065290A (en) * | 1975-07-03 | 1977-12-27 | Eli Lilly And Company | Herbicidal β-phenyl-4-piperidinones |
| US4060533A (en) * | 1976-06-25 | 1977-11-29 | Sandoz, Inc. | Pyranone carboxamides |
-
1980
- 1980-03-27 US US06/134,385 patent/US4304728A/en not_active Expired - Lifetime
- 1980-03-31 ES ES490121A patent/ES8104267A1/es not_active Expired
- 1980-03-31 IL IL59747A patent/IL59747A/xx unknown
- 1980-04-01 AU AU57032/80A patent/AU536369B2/en not_active Expired - Fee Related
- 1980-04-01 FI FI801019A patent/FI801019A7/fi not_active Application Discontinuation
- 1980-04-01 DE DE19803012584 patent/DE3012584A1/de not_active Withdrawn
- 1980-04-01 PH PH23843A patent/PH16517A/en unknown
- 1980-04-01 SE SE8002514A patent/SE8002514L/xx not_active Application Discontinuation
- 1980-04-01 DK DK142080A patent/DK142080A/da not_active IP Right Cessation
- 1980-04-02 AT AT0181980A patent/AT371456B/de not_active IP Right Cessation
- 1980-04-02 ZA ZA00801978A patent/ZA801978B/xx unknown
- 1980-04-02 CH CH258880A patent/CH645370A5/fr not_active IP Right Cessation
- 1980-04-02 PT PT71049A patent/PT71049A/pt unknown
- 1980-04-02 IE IE670/80A patent/IE49658B1/en unknown
- 1980-04-02 NZ NZ193344A patent/NZ193344A/xx unknown
- 1980-04-02 HU HU80786A patent/HU182115B/hu unknown
- 1980-04-02 GR GR61606A patent/GR67747B/el unknown
- 1980-04-02 FR FR8007448A patent/FR2453169A1/fr active Granted
- 1980-04-03 CA CA000349146A patent/CA1142526A/en not_active Expired
- 1980-04-03 BE BE6/47125A patent/BE882643A/fr not_active IP Right Cessation
- 1980-04-03 PL PL1980230342A patent/PL123812B1/pl unknown
- 1980-04-03 PL PL1980223228A patent/PL123699B1/pl unknown
- 1980-04-03 PL PL1980230341A patent/PL123813B1/pl unknown
- 1980-04-03 YU YU00919/80A patent/YU91980A/xx unknown
- 1980-04-03 PL PL1980230343A patent/PL123811B1/pl unknown
- 1980-04-03 GB GB08312569A patent/GB2123813B/en not_active Expired
- 1980-04-03 DD DD80220216A patent/DD150001A5/de unknown
- 1980-04-03 GB GB8011362A patent/GB2047698B/en not_active Expired
- 1980-04-04 CS CS816158A patent/CS222199B2/cs unknown
- 1980-04-04 LU LU82335A patent/LU82335A1/fr unknown
- 1980-04-04 IT IT48347/80A patent/IT1143085B/it active
- 1980-04-04 NL NL8002024A patent/NL8002024A/nl not_active Application Discontinuation
- 1980-04-04 CS CS802360A patent/CS222186B2/cs unknown
- 1980-04-04 JP JP4454980A patent/JPS55133375A/ja active Pending
- 1980-04-04 CS CS816156A patent/CS222197B2/cs unknown
- 1980-04-04 CS CS615781A patent/CS222198B2/cs unknown
- 1980-04-05 RO RO108190A patent/RO84586B/ro unknown
- 1980-04-05 RO RO80100748A patent/RO80248A/ro unknown
- 1980-04-05 RO RO108192A patent/RO84583B/ro unknown
- 1980-04-07 AR AR280565A patent/AR224149A1/es active
-
1981
- 1981-03-10 SU SU813254246A patent/SU1083909A3/ru active
- 1981-09-07 AR AR286667A patent/AR226126A1/es active
- 1981-09-07 AR AR286668A patent/AR226127A1/es active
- 1981-09-07 AR AR286666A patent/AR224318A1/es active
- 1981-09-17 US US06/303,297 patent/US4448787A/en not_active Expired - Fee Related
- 1981-11-27 FR FR8122254A patent/FR2493147A1/fr active Granted
-
1983
- 1983-05-20 US US06/496,704 patent/US4471129A/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 1. Эльдерфильд Р. Гетероциклические соединени , М., Изд-во Иностранна литература, 1954, т. 2, , с. 196. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1087205A (en) | 2-amino-3-(5-and 6-)benzoylphenylacetic acids, esters and metal salts thereof | |
| US4238492A (en) | Phenoxyalkylcarboxylic acids | |
| US3484445A (en) | Derivatives of chromone-2-carboxylic acid | |
| US3517051A (en) | Phenoxy substituted phenylacetic acids | |
| US4113871A (en) | Hypoglycemically and hypolipidemically active derivatives of phenyl-alkane-carboxylic acids | |
| SU976850A3 (ru) | Способ получени производных 5-замещенных @ -пиронов | |
| IL23152A (en) | Alkanoic acids are converted by aryl groups | |
| US4028404A (en) | Acetic acid derivatives | |
| US4526894A (en) | Pharmaceutically active 4-hydroxy-3-benzoyl-2-quinolone derivatives | |
| SU1083909A3 (ru) | Способ получени 6-замещенных производных пиранона | |
| US5399584A (en) | Use of flavone derivatives for gastroprotection | |
| US4950818A (en) | Method for treating ulcer | |
| JPH0227326B2 (enExample) | ||
| JPS58159459A (ja) | １―フェニル―２―アミノカルボニルインドール化合物および該化合物を含有する抗不整脈剤 | |
| HUP0004223A2 (hu) | 4-Oxo-butánsav-származékok és ezeket hatóanyagként tartalmazó gyógyászati készítmények | |
| JPH0222059B2 (enExample) | ||
| US3655743A (en) | Substituted 4 - biphenyl-4-hydroxy crotonic acids and salts thereof | |
| JPH0278675A (ja) | ベンゾフラニル酢酸誘導体、その製法、粘液調節剤および抗ヒスタミン剤 | |
| NL8204062A (nl) | Derivaten van 4-fenyl-4-oxo-2-buteenzuur en zouten daarvan, farmaceutische preparaten op basis daarvan en werkwijze voor het bereiden van een en ander. | |
| US4205087A (en) | Acetic acid derivatives | |
| JPH01250316A (ja) | 抗脂血剤 | |
| US4116972A (en) | Anti-inflammatory 1-oxo-isoindoline derivatives and processes for their preparation | |
| US4335048A (en) | 5-(2-Hydroxypropoxy)-8-propyl-4H-1-benzopyran-4-one-2-carboxylic acid | |
| US4558046A (en) | Substituted carboxy-thiazolo [3,2-a] pyrimidine derivatives and process for their preparation | |
| JPH0422901B2 (enExample) |